How Much Boswellia Per Day? Dosage and Safety

Most clinical trials on Boswellia serrata have used between 300 and 1,050 mg of extract per day, depending on the condition being treated. That range sounds tidy, but the real-world picture is messier: the potency of boswellic acids varies sharply between species and even between brands, absorption shoots up when you take it with fatty food, and some supplements on the shelf contain little to no active ingredient at all. Getting the dose right means understanding more than just a number on a label.

What the Osteoarthritis Trials Used

Knee osteoarthritis is where Boswellia has the strongest human evidence, so it is the best place to anchor a dosage discussion. A three-arm trial compared two doses of a standardized extract head-to-head against placebo: 150 mg per day and 300 mg per day. Both groups saw pain improvements within five days. By 90 days, the lower dose reduced pain scores by about 45% and the higher dose by about 62%, with similar patterns across stiffness, physical function, and walking distance.¹ The 300 mg dose outperformed 150 mg on almost every measure, which suggests a genuine dose-response relationship rather than a ceiling effect at the lower amount.

Another placebo-controlled trial used roughly 340 mg of extract per day (two tablets of about 170 mg each), standardized to contain around 175 mg of total boswellic acids, for 120 days. Pain, stiffness, and inflammatory markers all improved significantly, and radiographic assessments showed better joint spacing and reduced bone spurs.² An earlier crossover study in 30 patients also found significant improvements in knee pain, flexion, and walking distance over eight weeks, though the specific milligram dose of extract varied by formulation.³

If you are taking Boswellia specifically for joint pain, the evidence clusters around 150 to 340 mg of a standardized extract daily. Higher doses within that window appear to work somewhat better. But “standardized” is doing heavy lifting in that sentence, and the boswellic acid content behind the milligram number matters enormously.

Doses for Inflammatory Bowel Conditions

For gut inflammation, trials have used considerably more Boswellia than the osteoarthritis studies. In one trial, 20 patients with chronic colitis received 900 mg per day of Boswellia gum resin, split into three doses, for six weeks. Eighteen of the 20 showed improvement in stool properties, histopathology, and blood markers, and 14 achieved remission, compared to four out of ten in the sulfasalazine control group.⁴

For ulcerative colitis, 350 mg taken three times daily (about 1,050 mg total) achieved remission in about 82% of treated patients over six weeks, compared to 75% taking standard sulfasalazine. Some trials have gone as high as 2 grams per day, and a systematic review noted that Boswellia was roughly as effective as mesalazine in ulcerative colitis management.⁵⁶

The gap between the 300 mg doses used for joints and the 900 to 2,000 mg doses used for bowel disease is partly about the condition itself and partly about the formulation. Joint trials often use concentrated, highly standardized extracts with enhanced absorption, while older gut-inflammation trials used cruder gum resin preparations where more raw material was needed to deliver a therapeutic dose.

Why You Should Take It with Food

Boswellic acids are fat-soluble, and absorption on an empty stomach is remarkably poor. A pharmacokinetic study in healthy volunteers found that taking a Boswellia extract alongside a high-fat meal led to several-fold increases in the plasma concentrations of the key boswellic acids. Two of the active compounds, alpha-boswellic acid and its acetylated form, were not even detectable in the blood when the extract was taken in a fasted state. They only appeared in measurable amounts after the high-fat meal.⁷

This has practical implications that most supplement labels ignore. If you swallow a Boswellia capsule with a glass of water first thing in the morning, you could be absorbing a fraction of the active compounds that the clinical trials measured. Taking it with a meal that contains some fat, even something as simple as eggs, avocado, or a handful of nuts, can make a meaningful difference in how much actually reaches your bloodstream.

Enhanced-Absorption Formulations

Some manufacturers address the bioavailability problem by formulating Boswellia extract with phospholipids, typically soy lecithin, to create a complex sometimes called a phytosome. One such formulation, Casperome, was tested in mice alongside the same non-formulated extract at equivalent doses. The phytosome form produced plasma levels of the key compound KBA up to seven times higher, and brain concentrations of both KBA and AKBA that were roughly 35 times higher.⁸ A separate study confirmed that phosphatidylcholine complexes significantly enhanced absorption compared to plain boswellic acid, and phytosomes showed the strongest anti-inflammatory activity among several vesicular systems tested.⁹

This matters for dosing because a phytosome formulation at 250 mg could deliver more active compound to tissues than a plain extract at 500 mg. If a product uses one of these enhanced delivery systems, the effective dose may be lower than what the older clinical trials used, but you would need to look at the specific product’s own trial data to know by how much. The headline milligram number on the bottle is not the whole story.

How Quickly Effects Appear

People often expect herbal supplements to take weeks before anything noticeable happens, and for many supplements that is true. Boswellia can be faster. The three-arm osteoarthritis trial found statistically significant improvements in pain scores within five days in both the 150 mg and 300 mg groups.¹ Effects continued to build over the 90-day trial period, with the larger improvements appearing at later time points. The colitis trials ran for six weeks, and the 120-day osteoarthritis trial saw continued gains throughout. So while early relief is possible, the full benefit seems to develop over months of consistent use.

Combining Boswellia with Curcumin

Boswellia and curcumin (from turmeric) are frequently combined in joint-health supplements, and there is some clinical backing for the pairing. A placebo-controlled trial found that a combination of curcumin and boswellic acid was more effective at reducing osteoarthritis pain than curcumin alone, suggesting a synergistic interaction between the two.¹⁰ However, a meta-analysis noted that while the combination significantly improved pain compared to placebo, it did not produce statistically significant benefits on functional outcomes like mobility and physical performance.¹¹ Pain relief without matching functional improvement is a pattern worth noting if you are choosing between a standalone Boswellia extract and a combination product.

Side Effects and Tolerability

Across clinical trials, Boswellia has a consistent record of being well tolerated. The 120-day osteoarthritis trial reported no serious adverse events.² A 90-day trial using 300 mg of Boswellia alongside celery seed extract found no adverse effects on clinical examination, bloodwork, or ECG.¹² The gastrointestinal side effects that sometimes appear, such as nausea, acid reflux, or diarrhea, tend to be mild and infrequent. Compared to NSAIDs, which carry well-documented risks to the stomach lining and cardiovascular system, Boswellia is expected to have better tolerability, though researchers have noted this advantage still needs more rigorous head-to-head confirmation.¹³

Animal toxicity studies add some reassurance at higher doses. A 28-day repeated-dose study in rats found no signs of toxicity at doses up to 1,000 mg per kilogram of body weight per day.¹⁴ A 90-day study set the no-observed-adverse-effect level at 500 mg per kilogram per day in both male and female rats, with no changes in organ weights, thyroid hormones, or tissue pathology.¹⁵¹⁶ Translating animal doses to human equivalents is never straightforward, but these numbers provide a comfortable margin above the doses used in human trials. Animal data also suggests that Boswellia may actually protect liver tissue from certain types of damage rather than causing it.¹⁷

Drug Interactions Worth Knowing About

This is where caution is warranted. Lab studies have identified Boswellia extracts from multiple species as broad inhibitors of the cytochrome P450 enzymes that your liver uses to process a wide range of medications. The affected enzymes include CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4.¹⁸ CYP3A4 alone handles the metabolism of roughly half of all prescription drugs. If Boswellia slows these enzymes down, it could cause other medications to build up to higher levels in your blood than intended. This is an in-vitro finding, meaning it was demonstrated in lab conditions rather than proven in human drug interaction studies, but the breadth of enzymes affected is enough to warrant a conversation with a pharmacist or doctor if you take prescription medications regularly.

Separately, boswellic acids have been shown to inhibit COX-1, the same enzyme targeted by aspirin and ibuprofen. The most potent compound, AKBA, blocked COX-1 activity in human platelets at concentrations that could plausibly be reached with oral dosing, and the binding was reversed by ibuprofen, suggesting they compete for the same site.¹⁹ This raises two practical concerns. First, stacking Boswellia with NSAIDs could amplify gastrointestinal or bleeding risks beyond what either would cause alone. Second, if you take low-dose aspirin for cardiovascular protection, competition at the COX-1 binding site could theoretically interfere with aspirin’s antiplatelet effect. Neither of these interactions has been formally confirmed in clinical trials, but the mechanistic evidence is strong enough that caution makes sense.

The Supplement Quality Problem

Even if you land on the right dose, you might not be getting what you think. A survey of the top-selling Boswellia supplements in Europe and the United States found that only five out of seventeen products disclosed the species used, the plant part (resin), and the boswellic acid content. About 41% of the products tested did not match their label claims. One Italian product contained none of the six characteristic boswellic acids at all. A U.S. product contained only trace amounts. Another product’s boswellic acid ratios suggested it came from a completely different Boswellia species than the one listed on the label. Two products turned out to contain artificially enriched extracts with AKBA concentrations as high as 66%, which they did not disclose.²⁰

This makes dosing advice inherently fuzzy. A clinical trial uses a batch-tested, analytically verified extract where researchers know the exact boswellic acid content. A consumer buying a retail supplement may be getting a product with half the claimed potency, no potency at all, or an undisclosed species substitution. If precision matters to you, look for products that list the specific boswellic acid content (not just total extract weight), ideally with third-party testing verification.

Not All Frankincense Is the Same

Boswellia serrata, from India, is the species used in the vast majority of clinical research. But supplements sometimes contain or substitute other species, and the chemistry differs substantially. A quantitative analysis found that Boswellia sacra (from Oman and Yemen) contained roughly 49% boswellic acids by dry weight, compared to about 30% in B. serrata. More strikingly, the AKBA content, which is the most studied anti-inflammatory compound, was about 7% in B. sacra versus 0.7% in B. serrata, a tenfold difference.²¹

Meanwhile, B. sacra and B. carterii (Somalian frankincense) are sometimes treated as synonyms in the supplement world, but chemical analysis has shown they are distinct species with different volatile profiles and optical properties.²² A broader comparative study of four commercially relevant species, B. sacra, B. serrata, B. papyrifera, and B. frereana, identified over 200 compounds and found that each species could be clearly distinguished by its chemical fingerprint.²³ B. frereana is particularly notable because it lacks the key boswellic acids entirely, which is likely why the quality survey found a product suspected of using it that had no detectable active compounds.

Higher AKBA content does not automatically mean a B. sacra supplement is “better.” The clinical dosing data comes from B. serrata trials, and the anti-inflammatory effects of Boswellia involve multiple boswellic acids working together, not just AKBA in isolation. But if a supplement swaps in a different species without disclosing it, the dose-response relationship from published research no longer applies, and you are essentially dosing blind.

Children, Pregnancy, and Gaps in the Evidence

Published literature contains no adverse events specifically linked to Boswellia use in children, but that absence reflects a lack of study rather than confirmed safety. No systematic trials have established pediatric dosing.²⁴ For pregnant or breastfeeding women, the evidence gap is even wider. Animal reproductive toxicity studies have not flagged obvious problems, but the standard recommendation from most clinical references is to avoid use during pregnancy due to insufficient data. This is the default stance for nearly all herbal supplements, not a specific red flag for Boswellia.

How Boswellia Actually Works in the Body

Boswellia’s anti-inflammatory effects come primarily from its boswellic acids, a group of compounds found in the resin. The most studied of these, AKBA (acetyl-11-keto-β-boswellic acid), is a potent inhibitor of the enzyme 5-lipoxygenase, which drives a major inflammation pathway.²⁵ But the activity is broader than just one enzyme. Research has shown that boswellic acids also suppress NFκB (a master switch for inflammatory gene activation) and COX-2 (the enzyme targeted by drugs like celecoxib), reducing both inflammation and cartilage breakdown.²⁶ Hitting multiple inflammatory pathways at once is part of what makes Boswellia interesting compared to single-target drugs, though it also makes predicting interactions more complicated.

This multi-pathway mechanism helps explain why Boswellia shows up in trials for such different conditions. Joint inflammation, gut inflammation, and airway inflammation are driven by overlapping but not identical molecular signals, and a compound that suppresses several of those signals at once has a broader potential range of action than one that targets only COX-2 or only 5-lipoxygenase. Whether that breadth translates into clinical superiority over conventional anti-inflammatories remains an open question, with head-to-head trials still thin on the ground.